MTOR inhibitors: A novel class of anti-cancer agents

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Riaz, Haris ^a,b   Riaz, Talha ^a   Hussain, Syed A ^c  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b CIVIL HOSPITAL   (Pakistan)

^c DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DNA TOPOISOMERASE INHIBITOR; EVEROLIMUS; GYRASE INHIBITOR; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; OSI 027; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 765;

ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KIDNEY CARCINOMA; LETTER; MANTLE CELL LYMPHOMA; MUTATION; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL;

EID: 84855229511     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-1     Document Type: Letter

References (10)

1. Current development of mTOR inhibitors as anticancer agents. Faivre S, Kroemer G, Raymond E, Nature Reviews Drug Discovery 2006 5 671 688 10.1038/nrd2062 16883305 (Pubitemid 44151605)
2. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Beevers C, Li F, Liu L, Huang S, Int J Cancer 2006 119 4 757 64 10.1002/ijc.21932 16550606 (Pubitemid 44051438)
3. Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. Gaur S, Chen L, Yang L, Wu X, Un F, Yen Y, Cancer Lett 2011 311 1 20 8 10.1016/j.canlet.2011.06.005 21764510
4. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J, Reid GS, Seif AE, Norris R, Chang YJ, Carroll M, Grupp SA, Blood 2008 112 5 2020 3 10.1182/blood-2008-02-137141 18544682
5. Rapamycins: mechanism of action and cellular resistance. Huang S, Bjornsti M, Houghton P, Cancer BiolTher 2003 2 222 232
6. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Borders EB, Bivona C, Medina PJ, Am J Health Syst Pharm 2010 67 24 2095 106 10.2146/ajhp100020 21116000
7. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Akhavan D, Cloughesy TF, Mischel PS, NeuroOncol 2010 12 8 882 9
8. The Biology Behind mTOR Inhibition in Sarcoma. XiaolinWan Lee J, Helman, The Oncologist Aug 2007 12 1007 1018 (Pubitemid 47359144)
9. Targeting mTOR-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses. Furic L, Livingstone M, Dowling RJO, Sonenberg N, Current oncology 2009 16 68 71
10. Targeting mTOR globally in cancer: thinking beyond rapamycin. Shor B, Gibbons JJ, Abraham RT, Yu K, Cell Cycle 2009 8 23 3831 7 10.4161/cc.8.23.10070 19901542